These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 36120577)

  • 1. Pan-cancer analysis identifies YTHDF2 as an immunotherapeutic and prognostic biomarker.
    Liu W; Liu C; You J; Chen Z; Qian C; Lin W; Yu L; Ye L; Zhao L; Zhou R
    Front Cell Dev Biol; 2022; 10():954214. PubMed ID: 36120577
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive analysis of m6A reader YTHDF2 prognosis, immune infiltration, and related regulatory networks in hepatocellular carcinoma.
    Wang H; Cai H; Li L
    Heliyon; 2024 Jan; 10(1):e23204. PubMed ID: 38163150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic Analyses of the Role of the Reader Protein of
    Shao XY; Dong J; Zhang H; Wu YS; Zheng L
    Front Mol Biosci; 2020; 7():577460. PubMed ID: 33344502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N6-methyladenosine methylation-related genes
    Wang Y; Li T; Liu H; Liang Y; Wang G; Fu G; Takatsuki M; Qu H; Jing F; Li J; Jiang M
    Ann Transl Med; 2022 Dec; 10(24):1398. PubMed ID: 36660669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YTHDF2 negatively correlates with tumor immune infiltration in small cell lung cancer.
    Chen G; Ren D; Wang Y; Wang H; Zhang J; Yang S
    J Mol Histol; 2023 Aug; 54(4):365-377. PubMed ID: 37357252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biological function of m6A reader YTHDF2 and its role in human disease.
    Wang JY; Lu AQ
    Cancer Cell Int; 2021 Feb; 21(1):109. PubMed ID: 33593354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. m
    Tan Z; Hei F; Ma K; Lv Z; Zhang H; Sun N; Guo W; Song M
    Int Immunopharmacol; 2024 Dec; 142(Pt B):113079. PubMed ID: 39288628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
    Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
    Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m
    Chen X; Zhou X; Wang X
    Exp Hematol Oncol; 2022 Apr; 11(1):21. PubMed ID: 35382893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
    Tsuchiya K; Yoshimura K; Inoue Y; Iwashita Y; Yamada H; Kawase A; Watanabe T; Tanahashi M; Ogawa H; Funai K; Shinmura K; Suda T; Sugimura H
    Oncoimmunology; 2021; 10(1):1962656. PubMed ID: 34408926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
    Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
    PeerJ; 2022; 10():e14432. PubMed ID: 36518297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma.
    Su G; Liu T; Han X; Sun H; Che W; Hu K; Xiao J; Li Y; Liu Y; Li W; Mei H
    Front Pharmacol; 2021; 12():709548. PubMed ID: 34512342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-Cancer Analysis Based on
    Zhang Y; Wang S; Han S; Feng Y
    Front Oncol; 2022; 12():844794. PubMed ID: 35359375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 18. ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis.
    Ning Y; Li Y; Wang H
    Front Genet; 2023; 14():1108167. PubMed ID: 36713082
    [No Abstract]   [Full Text] [Related]  

  • 19. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation.
    Bai X; Chen J; Zhang W; Zhou S; Dong L; Huang J; He X
    Cancer Sci; 2023 Nov; 114(11):4299-4313. PubMed ID: 37700438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.